LifeMD Statistics
Total Valuation
LifeMD has a market cap or net worth of $199.74 million. The enterprise value is $171.43 million.
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LifeMD has 48.36 million shares outstanding. The number of shares has increased by 9.51% in one year.
| Current Share Class | 48.36M |
| Shares Outstanding | 48.36M |
| Shares Change (YoY) | +9.51% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 13.60% |
| Owned by Institutions (%) | 37.38% |
| Float | 40.08M |
Valuation Ratios
The trailing PE ratio is 78.05 and the forward PE ratio is 28.23.
| PE Ratio | 78.05 |
| Forward PE | 28.23 |
| PS Ratio | 1.03 |
| Forward PS | 0.86 |
| PB Ratio | 13.05 |
| P/TBV Ratio | 50.89 |
| P/FCF Ratio | 32.01 |
| P/OCF Ratio | 24.66 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 66.99 |
| EV / Sales | 0.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 27.47 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.04 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.99 |
| Interest Coverage | -17.18 |
Financial Efficiency
Return on equity (ROE) is -238.45% and return on invested capital (ROIC) is -41.97%.
| Return on Equity (ROE) | -238.45% |
| Return on Assets (ROA) | -13.41% |
| Return on Invested Capital (ROIC) | -41.97% |
| Return on Capital Employed (ROCE) | -75.06% |
| Weighted Average Cost of Capital (WACC) | 15.05% |
| Revenue Per Employee | $549,234 |
| Profits Per Employee | $7,270 |
| Employee Count | 352 |
| Asset Turnover | 2.69 |
| Inventory Turnover | 8.30 |
Taxes
In the past 12 months, LifeMD has paid $45,721 in taxes.
| Income Tax | 45,721 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.83% in the last 52 weeks. The beta is 1.98, so LifeMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -67.83% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 4.40 |
| Relative Strength Index (RSI) | 40.50 |
| Average Volume (20 Days) | 971,506 |
Short Selling Information
The latest short interest is 5.59 million, so 11.55% of the outstanding shares have been sold short.
| Short Interest | 5.59M |
| Short Previous Month | 5.85M |
| Short % of Shares Out | 11.55% |
| Short % of Float | 13.94% |
| Short Ratio (days to cover) | 5.67 |
Income Statement
In the last 12 months, LifeMD had revenue of $193.33 million and earned $2.56 million in profits. Earnings per share was $0.06.
| Revenue | 193.33M |
| Gross Profit | 167.83M |
| Operating Income | -15.42M |
| Pretax Income | -17.41M |
| Net Income | 2.56M |
| EBITDA | -14.30M |
| EBIT | -15.42M |
| Earnings Per Share (EPS) | $0.06 |
Full Income StatementBalance Sheet
The company has $34.48 million in cash and $6.17 million in debt, giving a net cash position of $28.31 million or $0.59 per share.
| Cash & Cash Equivalents | 34.48M |
| Total Debt | 6.17M |
| Net Cash | 28.31M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 15.04M |
| Book Value Per Share | 0.32 |
| Working Capital | 2.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.10 million and capital expenditures -$1.86 million, giving a free cash flow of $6.24 million.
| Operating Cash Flow | 8.10M |
| Capital Expenditures | -1.86M |
| Depreciation & Amortization | 1.12M |
| Net Borrowing | -18.72M |
| Free Cash Flow | 6.24M |
| FCF Per Share | $0.13 |
Full Cash Flow StatementMargins
Gross margin is 86.81%, with operating and profit margins of -7.97% and 2.93%.
| Gross Margin | 86.81% |
| Operating Margin | -7.97% |
| Pretax Margin | -9.01% |
| Profit Margin | 2.93% |
| EBITDA Margin | -7.40% |
| EBIT Margin | -7.97% |
| FCF Margin | 3.23% |
Dividends & Yields
LifeMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.51% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.28% |
| FCF Yield | 3.12% |
Analyst Forecast
The average price target for LifeMD is $9.88, which is 139.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.88 |
| Price Target Difference | 139.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 15.98% |
| EPS Growth Forecast (3Y) | 73.87% |
Stock ForecastsStock Splits
The last stock split was on October 14, 2020. It was a reverse split with a ratio of 1:5.
| Last Split Date | Oct 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
LifeMD has an Altman Z-Score of 0.61 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 6 |